Paradigm Biopharmaceuticals Ltd
ASX:PAR
Paradigm Biopharmaceuticals Ltd
Net Income (Common)
Paradigm Biopharmaceuticals Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Paradigm Biopharmaceuticals Ltd
ASX:PAR
|
Net Income (Common)
-AU$15.6m
|
CAGR 3-Years
27%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Net Income (Common)
-$103.4m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Net Income (Common)
$2.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
6%
|
CAGR 10-Years
7%
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Net Income (Common)
AU$38.8m
|
CAGR 3-Years
17%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Net Income (Common)
AU$49.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Net Income (Common)
-AU$48.2m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-56%
|
CAGR 10-Years
-32%
|
|
Paradigm Biopharmaceuticals Ltd
Glance View
Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company, engages in researching and developing therapeutic products for human use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2015-08-19. The firm is developing and commercializing injectable Pentosan Polysulfate Sodium (PPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The firm focuses on repurposing PPS for the treatment of Osteoarthritis (OA) and bone marrow lesions (BML), chronic heart failure (CHF) and alphaviral arthritis (Ross River Virus and Chikungunya). Its product candidate PPS is a non-opioid drug treatment for the chronic pain and joint stiffness of Osteoarthritis. Its product candidate PPS is providing treatment for Mucopolysaccharidosis, an inherited defect in the catabolism of sulfated components of connective tissue known as glycosaminoglycans (GAGs). Its product candidate PPS is used to treat Ross River virus and Chikungunya, an arthritogenic alphaviruses transmitted by mosquito bites.
See Also
What is Paradigm Biopharmaceuticals Ltd's Net Income (Common)?
Net Income (Common)
-15.6m
AUD
Based on the financial report for Dec 31, 2024, Paradigm Biopharmaceuticals Ltd's Net Income (Common) amounts to -15.6m AUD.
What is Paradigm Biopharmaceuticals Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
1%
Over the last year, the Net Income (Common) growth was 78%. The average annual Net Income (Common) growth rates for Paradigm Biopharmaceuticals Ltd have been 27% over the past three years , 1% over the past five years .
You don't have any saved screeners yet